Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIAGARA-2: Perioperative durvalumab with cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer
2024-519246-75-01Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in muscle-invasive bladder carcinoma (MIBC), sponsored by AstraZeneca. Primary endpoint: Incidence of Grade 3 or 4 PRAEs prior to radical cystectomy. Planned start Jun 2026; status: authorised.
02
Drugs
durvalumab
03
Conditions
muscle-invasive bladder carcinoma (MIBC)
Beyond the preview
Go deeper on 2024-519246-75-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519246-75-01.